Participated · Equity · Aug 2021

Founded in 2017 and based in Melbourne, Seer Medical builds patient-centric home EEG solutions that combine cloud, web, and AI technologies. Its flagship product, Seer Home, enables long-term home-based video electroencephalography (EEG) monitoring to accelerate epilepsy detection without hospitalization. The company focuses on improving access to epilepsy diagnostics for patients and clinicians through remote monitoring and data-driven workflows. Seer Medical’s technology is positioned to integrate with larger clinical EEG portfolios and support ambulatory and hospital-based diagnostic centers. Recent investment activity is intended to expand technical capacity and help bring new products to market via partnerships with strategic investors. The articles do not disclose revenue, user, or valuation metrics. Seer is a medtech diagnostics company focused on epilepsy. It was founded in 2017 by Dean Freestone, George Kenley and Mark Cook. The company has raised $34 million from investors including Cochlear, multi‑family office EWM Group, SG Hiscock and impact investor Giant Leap. Cochlear is reported to have bought into the company. The article describes Seer as cashed up and ready to expand. The piece does not disclose operating metrics or the specific financing instruments.

Participated · Equity · Feb 2020

Nyxoah SA focuses on neuromodulation‐based solutions for obstructive sleep apnea, led by its flagship Genio system. The minimally invasive Genio implant delivers bilateral hypoglossal nerve stimulation intended to keep patients’ airways open during sleep. To accelerate growth, the company plans to launch commercial activities in the United States while expanding sales in its initial non-U.S. target markets. Newly raised capital will also fund additional clinical data collection, physician-initiated research, and R&D aimed at upgrading Genio, redesigning it for easier manufacturing, and lowering costs. Management intends to build a pipeline of new technologies and explore collaborations in OSA monitoring and diagnostics. Remaining proceeds may support working capital, capital expenditures, investments, acquisitions, and other general corporate purposes. The latest financing package provides up to roughly $77 million through a mix of equity and convertible debt, strengthening Nyxoah’s balance sheet for these initiatives.

Participated · Series C · Jun 2017

Earlens is a privately held medical technology company that developed the Earlens® hearing solution, a nonsurgical treatment that uses a small lens to vibrate the eardrum and replicate natural hearing. The company holds more than 185 U.S. and international patents and was named to Time Magazine's list of the top 100 inventions of 2020. Earlens products are available exclusively through a growing network of trained ENT physicians and audiologists supported by dedicated concierge customer service. With quarter-over-quarter revenue growth across 2021, the company said it is on pace to have its best year ever despite headwinds facing ENT practices and the hearing industry. The company recently closed another $25 million in funding and is looking to grow the team and invest in employee advancement and hiring. Leadership recognition—such as CEO Bill Facteau winning Comparably's "Best CEO" award—was highlighted alongside people-focused policies including competitive pay, benefits, and career-pathing. Earlens Corporation develops the Earlens Light-Driven Hearing Aid, a medical device that uses light to transmit sound to hearing-impaired patients. The company was incorporated in 2005 and is based in Menlo Park, California, with Bill Facteau as CEO. In late 2015 the FDA cleared a De Novo premarket submission allowing Earlens to market the Light-Driven Hearing Aid. Earlens closed a $118M debt and equity financing to support its operations. The company intends to use the proceeds for commercialization of the Light-Driven Hearing Aid, manufacturing scale-up, and R&D. The financing positions the company to advance commercial rollout of its core product. Earlens has developed the Earlens Light-Driven Hearing Aid, a device that uses focused light and a small lens resting on the eardrum to transmit sound and improve understanding in noisy environments for people with mild to severe sensorineural hearing impairment. The company received FDA De Novo clearance in late 2015, allowing it to market the Light-Driven Hearing Aid. Earlens is preparing for a commercial launch of the device and is pursuing additional financing to support that launch. The firm announced a Series C first close totaling $51 million, composed of $34 million in new capital and $17 million in conversion of an outstanding bridge financing. Management expects to complete the financing in the third quarter of 2016 by raising an additional $14 million. The companies and investors participating in the round are supporting the company’s move toward commercialization.